Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559962 · ClinicalTrials.gov registry record · Phase 2
Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
A Phase 2 study of Hyperlipidemia, sponsored by Aegerion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
- 15
- Study locations
NCT00559962: Completed Phase 2 study of Hyperlipidemia, sponsored by Aegerion Pharmaceuticals.
NCT00559962 is a Phase 2 study of Hyperlipidemia that has completed, run by Aegerion Pharmaceuticals. The registered enrollment target is 260 participants, below the 400-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (35% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00559962, a Phase 2 study of Hyperlipidemia, has completed, sponsored by Aegerion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
- 15
- Study locations
Study Summary
To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy
Primary Outcome
Absolute change from Baseline in percent hepatic fat
Conditions Studied
Interventions
- DRUG placebo
- DRUG AEGR-733
Study Locations (15)
Texas
- Baylor College of Medicine - Houston
- Clinical Trial Network - Houston
- dgd Research - San Antonio
California
- Scripps Clinic - San Diego
- Radiant Research - Santa Rosa
Maryland
- Health Trends Research - Baltimore
- Johns Hopkins - Baltimore
District of Columbia
- MedStar Research Institute - Washington D.C.
Illinois
- Radiant Research - Chicago
Iowa
- University of Iowa - Iowa City
Kentucky
- LMARC - Louisville
Maine
- Maine Research Associates - Auburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
What the finished NCT00559962 record still lists
NCT00559962 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 400-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00559962 lists 15 locations in 11 states (Texas, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT00559962 about?
NCT00559962 is a clinical study titled "Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS". To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy
What is the current status of trial NCT00559962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2007-10. Estimated completion is 2008-11.
What conditions does trial NCT00559962 study?
This clinical trial studies the following conditions: Hyperlipidemia.
What interventions are being tested in trial NCT00559962?
The interventions under investigation include: placebo (DRUG), AEGR-733 (DRUG).
Who is sponsoring clinical trial NCT00559962?
This trial is sponsored by Aegerion Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00559962 being conducted?
This trial has 15 study locations across California, District of Columbia, Illinois, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00559962's enrollment target sits among peer trials
260 12th of 35 higher than 24 of 35 other Hyperlipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperlipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
COMPLETED · Phase 2
-
The SCCS Polypill Pilot Trial
COMPLETED · Phase 2
-
Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
COMPLETED · Phase 2
-
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
COMPLETED · Phase 2
-
Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia